Exacerbation severity and frequency are crucial for the prognosis of COPD, but also appear to have a major impact on the course of comorbidities. There is a growing body of evidence showing that COPD patients are at increased risk of cardiovascular events, with the frequency and severity of exacerbations being important predictors. Optimal treatment of COPD also appears to reduce the risk of concomitant diseases. Depending on the situation, it may make sense to extend dual bronchodilation with inhaled steroids or roflumilast as an add-on.
Autoren
- Mirjam Peter, M.Sc.
Publikation
- HAUSARZT PRAXIS
Related Topics
You May Also Like
- Clinical significance, pathophysiology, diagnosis and management
Frailty in COPD
- Bladder infections and urinary tract infections
Survey reveals information deficits in the population
- Early detection of type 1 diabetes
Detection of insulin autoantibodies as an early marker
- Type 2 diabetes
Smoking causes more than double the risk
- From symptom to diagnosis
Abdominal pain – Colitis
- Pathophysiology, cardiovascular consequences and metabolic interventions
Obesity accelerates cardiovascular ageing
- CKD: counteracting kidney progression and reducing the risk of CVD
Targeted intervention through a multifactorial approach
- COPD therapy